Results from a new study published in JAMA find that among patients with major depressive disorder (MDD), a single 25-mg dose of psilocybin led to a steady reduction in depressive symptoms and helped improve psychosocial functioning. The goal of the research was to examine the safety and efficacy of using psilocybin in patients with MDD.

The popular GLP-1 receptor agonists, originally approved for T2D, may also be beneficial for patients with T1D—at least, that’s what findings from a small study published in NEJM imply.

A new report from CDC finds that in recent years, the number of people who overdosed and died from counterfeit prescription drugs has more than doubled. From mid-2019 to the end of 2021, overdose deaths involving counterfeit drugs increased from 2% to 4.7%.

Findings from a recent study published in JAMA Network Open suggest that postnatal SSRI treatment may bring benefits in the long term to not only mothers, but also their offspring.

According to a new recommendation statement published in JAMA, the U.S. Preventive Services Task Force (USPSTF) recommends PrEP for those at high risk of contracting HIV to comprise newer antiretroviral drugs, including a long-acting option.